Predicting T Cell Receptor Antigen Specificity From Structural Features Derived From Homology Models of Receptor-Peptide-Major Histocompatibility Complexes

The physical interaction between the T cell receptor (TCR) and its cognate antigen causes T cells to activate and participate in the immune response. Understanding this physical interaction is important in predicting TCR binding to a target epitope, as well as potential cross-reactivity. Here, we propose a way of collecting informative features of the binding interface from homology models of T cell receptor-peptide-major histocompatibility complex (TCR-pMHC) complexes.

The information collected from these structures is sufficient to discriminate binding from non-binding TCR-pMHC pairs in multiple independent datasets. The classifier is limited by the number of crystal structures available for the homology modelling and by the size of the training set. However, the classifier shows comparable performance to sequence-based classifiers requiring much larger training sets.

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor–T Cell Therapy

Ewing’s sarcoma (EWS) is a malignant and aggressive tumor type that predominantly occurs in children and adolescents. Traditional treatments such as surgery, radiotherapy and chemotherapy, while successful in the early disease stages, are ineffective in patients with metastases and relapses who often have poor prognosis. Therefore, new treatments for EWS are needed to improve patient’s outcomes.

Chimeric antigen receptor (CAR)-T cells therapy, a novel adoptive immunotherapy, has been developing over the past few decades, and is increasingly popular in researches and treatments of various cancers. CAR-T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of leukemia and lymphoma. Recently, this therapeutic approach has been employed for solid tumors including EWS. In this review, we summarize the safety, specificity and clinical transformation of the treatment targets of EWS, and point out the directions for further research.

Autologous Transplant versus Chimeric Antigen Receptor T–cell Therapy for Relapsed DLBCL in Partial Remission

The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) versus chimeric antigen receptor T-cell (CAR-T) therapy in diffuse large B-cell lymphoma (DLBCL) patients who achieve a partial remission (PR) after salvage chemotherapy is not known. Using the Center for International Blood & Marrow Transplant Research registry database, we identified adult DLBCL patients who received either an auto-HCT (2013-2019) or CAR-T treatment with axicabtagene ciloleucel while in a PR by CT or PET scan.

We compared the clinical outcomes between the two cohorts using univariable and multivariable regression models after adjustment for relevant baseline and clinical factors. In the univariable analysis, the 2-year progression-free survival and the rate of 100-day non-relapse mortality (4% vs. 2% ; p=0.3) were not different between the 2 cohorts but consolidation with auto-HCT was associated with a lower rate of relapse/progression (40% vs. 53% ; p=0.05) and a superior overall survival (OS) at 2-years.

In the multivariable regression analysis, treatment with auto-HCT was associated with a significantly lower risk of relapse/progression rate (HR=1.49; p=0.01) and a superior OS (HR=1.63; p=0.008). In patients with DLBCL in a PR after salvage therapy, treatment with auto-HCT was associated with a lower incidence of relapse and a superior OS compared with CAR-T. These data support the role of auto-HCT as the standard-of-care in transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.

Distinct single-component adjuvants steer human DC-mediated T–cell polarization via Toll-like receptor signaling toward a potent antiviral immune response

The COVID-19 pandemic highlights the importance of efficient and safe vaccine development. Vaccine adjuvants are essential to boost and tailor the immune response to the corresponding pathogen. To allow for an educated selection, we assessed the effect of different adjuvants on human monocyte-derived dendritic cells (DCs) and their ability to polarize innate and adaptive immune responses. In contrast to commonly used adjuvants, such as aluminum hydroxide, Toll-like receptor (TLR) agonists induced robust phenotypic and functional DC maturation.

In a DC-lymphocyte coculture system, we investigated the ensuing immune reactions. While monophosphoryl lipid A synthetic, a TLR4 ligand, induced checkpoint inhibitors indicative for immune exhaustion, the TLR7/8 agonist Resiquimod (R848) induced prominent type-1 interferon and interleukin 6 responses and robust CTL, B-cell, and NK-cell proliferation, which is particularly suited for antiviral immune responses.

Indeed, we could confirm that the cytokine profile induced by lipid-complexed RNA was almost identical to the pattern induced by R848. Although this awaits further investigation, our results suggest that their efficacy involves the highly efficient antiviral response pattern stimulated by the RNAs’ TLR7/8 activation.

CNS relapse of acute lymphocytic leukaemia is difficult to treat. Durable remissions of relapsed or refractory B-cell acute lymphocytic leukaemia have been observed following treatment with CD19-directed chimeric antigen receptor (CAR) T cells; however, most trials have excluded patients with active CNS disease. We aimed to assess the safety and activity of CAR T-cell therapy in patients with a history of CNS relapsed or refractory B-cell acute lymphocytic leukaemia.

In this post-hoc analysis, we included 195 patients (aged 1-29 years; 110 [56%] male and 85 [44%] female) with relapsed or refractory CD19-positive acute lymphocytic leukaemia or lymphocytic lymphoma from five clinical trials (Pedi CART19, 13BT022, ENSIGN, ELIANA, and 16CT022) done at the Children’s Hospital of Philadelphia (Philadelphia, PA, USA), in which participants received CD19-directed CAR T-cell therapy between April 17, 2012, and April 16, 2019.

The trials required control of CNS disease at enrolment and infusion and excluded treatment in the setting of acute neurological toxic effects (>grade 1 in severity) or parenchymal lesions deemed to increase the risk of neurotoxicity.The recently licensed COVID-19 vaccines, BNT162b and mRNA-1273, are both based on single-stranded RNA.

Long-term Cell Tracer 580 (Green) sample

P710GS 0.1 ml
EUR 199

Long-term Cell Tracer 580 (Yellow) sample

P710YS 0.1 ml
EUR 199

CFDA SE Cell Tracer Kit

K1023-1 1 kit
EUR 96
Description: Cell Biology|Cell Proliferation & Toxicity

FluoGreen Tracer, Stains Cell Nuclei and Cytoplasm

MBS555420-01mL 0.1mL
EUR 435

FluoGreen Tracer, Stains Cell Nuclei and Cytoplasm

MBS555420-5x01mL 5x0.1mL
EUR 1815

CFDA, SE Cell Proliferation and Tracer Assay Kit

CA1200
  • Ask for price
  • Ask for price
  • 1000 Tests
  • 2000 Tests

CFDA SE cell proliferation and tracer detection kit

ETF0051 2000 assays
EUR 300

CFDA SE cell prolifeRation and tracer detection kit

MBS8579509-2000Assays 2000Assays
EUR 400

CFDA SE cell prolifeRation and tracer detection kit

MBS8579509-5x2000Assays 5x2000Assays
EUR 1810

FluoGreen Tracer

SF41000 100 ul
EUR 292.05

Tau tracer 1

HY-134879 Get quote Ask for price
Description: Tau tracer 1 is a Tau tracer used for imaging Tau protein aggregates. Tau tracer 1 can be used to diagnose neurodegenerative diseases[1].

Tau tracer 2

HY-134880 10 mg
EUR 216.45
Description: Tau tracer 2 (Pl-2620) is a Tau tracer used for imaging Tau protein aggregates. Tau tracer 2 can be used to diagnose neurodegenerative diseases[1].

Tau tracer 1

MBS5800094-5mg 5(mg
EUR 915

Tau tracer 1

MBS5800094-5x5mg 5x5(mg
EUR 3970

Tau tracer 2

MBS5798041-50mg 50(mg
EUR 960

Tau tracer 2

MBS5798041-5x50mg 5x50(mg
EUR 4180

Tau tracer 2

T37051-10mg 10mg Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-1g 1g Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-1mg 1mg Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-50mg 50mg Ask for price
Description: Tau tracer 2

Tau tracer 2

T37051-5mg 5mg Ask for price
Description: Tau tracer 2

Tau tracer 1

T39660-10mg 10mg Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-1g 1g Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-1mg 1mg Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-50mg 50mg Ask for price
Description: Tau tracer 1

Tau tracer 1

T39660-5mg 5mg Ask for price
Description: Tau tracer 1

JAK2 JH2 Tracer

HY-102055 50mg
EUR 2705.67
Description: JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a Kd of value 0.2 μM[1][2].

JAK2 JH2 Tracer

MBS3844504-10mg 10mg
EUR 855

JAK2 JH2 Tracer

MBS3844504-1mg 1mg
EUR 225

JAK2 JH2 Tracer

MBS3844504-50mg 50mg
EUR 2450

JAK2 JH2 Tracer

MBS3844504-5mg 5mg
EUR 525

JAK2 JH2 Tracer

MBS3844504-5x50mg 5x50mg
EUR 11020

JAK2 JH2 Tracer

MBS5755856-50mg 50mg
EUR 2840

JAK2 JH2 Tracer

MBS5755856-5x50mg 5x50mg
EUR 12620

JAK2 JH2 Tracer

T19017-10mg 10mg Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-1g 1g Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-1mg 1mg Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-50mg 50mg Ask for price
Description: JAK2 JH2 Tracer

JAK2 JH2 Tracer

T19017-5mg 5mg Ask for price
Description: JAK2 JH2 Tracer

CytoFixâ„¢ BCECF, AM *Optimized for long term cellular pH tracking*

21200-1mg 1 mg
EUR 318
Description: Intracellular pH plays an important modulating role in many cellular events, including cell growth, calcium regulation, enzymatic activity, receptor-mediated signal transduction, ion transport, endocytosis, chemotaxis, cell adhesion and other cellular processes.

ROS tracer precursor

HY-126712 Get quote Ask for price
Description: ROS tracer precursor is the precursor of [18F]ROStrace for the synthesis of ROStrace, which can be used for disease diagnosis[1].

ROS tracer precursor

MBS5772039-5mg 5mg
EUR 915

ROS tracer precursor

MBS5772039-5x5mg 5x5mg
EUR 3970

ROS tracer precursor

T19550-10mg 10mg Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-1g 1g Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-1mg 1mg Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-50mg 50mg Ask for price
Description: ROS tracer precursor

ROS tracer precursor

T19550-5mg 5mg Ask for price
Description: ROS tracer precursor

BSA tracer Ultra Small

200.033 10 mL Ask for price

BSA tracer Ultra Small

200.133 5 mL Ask for price

Anionic tracer Ultra Small

200.022 10 mL Ask for price

Anionic tracer Ultra Small

200.122 5 mL Ask for price

Long-Term Cell Tracing Reagent CMAC (Blue)

EGY0171 100µg
EUR 92

Long-Term Cell Tracing Reagent CMAC (Blue)

EGY0172 5x100µg
EUR 340

Long-Term Cell Tracing Reagent CMAC (Blue)

MBS8579546-01mg 0.1mg
EUR 185

Long-Term Cell Tracing Reagent CMAC (Blue)

MBS8579546-5x01mg 5x0.1mg
EUR 420

Long-Term Cell Tracing Reagent CMFDA(Green)

EGY0181 100µg
EUR 220

Long-Term Cell Tracing Reagent CMFDA(Green)

EGY0182 5x100µg
EUR 500

Long-Term Cell Tracing Reagent CMFDA (Green)

MBS8579547-01mg 0.1mg
EUR 300

Long-Term Cell Tracing Reagent CMFDA (Green)

MBS8579547-5x01mg 5x0.1mg
EUR 580

Human EGF HRP Tracer Antibody

MP190220T 0.2 mL Ask for price

BSA tracer Conventional 6-nm

206.033 10 mL Ask for price

BSA tracer Conventional 6-nm

206.133 5 mL Ask for price

BSA tracer Conventional 10-nm

210.033 10 mL Ask for price

BSA tracer Conventional 10-nm

210.133 5 mL Ask for price

BSA tracer Conventional 15-nm

215.033 10 mL Ask for price

BSA tracer Conventional 15-nm

215.133 5 mL Ask for price

BSA tracer Conventional 25-nm

225.033 10 mL Ask for price

BSA tracer Conventional 25-nm

225.133 5 mL Ask for price

Human EGF Biotin Tracer Antibody

MP190220B 0.1 mg Ask for price

Anti-Human Prolactin HRP Tracer

MP100555T 200 µL Ask for price

Human Alpha Fetoprotein HRP Tracer

MP700120T 0.2 mL Ask for price

Anionic tracer Conventional 6-nm

206.022 10 mL Ask for price

Anionic tracer Conventional 6-nm

206.122 5 mL Ask for price

Anionic tracer Conventional 10-nm

210.022 10 mL Ask for price

Anionic tracer Conventional 10-nm

210.122 5 mL Ask for price

Anionic tracer Conventional 15-nm

215.022 10 mL Ask for price

Anionic tracer Conventional 15-nm

215.122 5 mL Ask for price

Anionic tracer Conventional 25-nm

225.022 10 mL Ask for price

Anionic tracer Conventional 25-nm

225.122 5 mL Ask for price

Anti-Human IL-8 HRP Tracer

MP800120T 0.2 mL Ask for price

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

EGY0161 100 µg
EUR 160

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

EGY0162 5 x 100 µg
EUR 340

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

MBS8579545-01mg 0.1mg
EUR 245

Long-Term Cell Tracing Reagent CDCFDA, SE (Green)

MBS8579545-5x01mg 5x0.1mg
EUR 420

Anti-Human IL-16 HRP Tracer

MP160160T 0.2 mL Ask for price

Anti-Human MCP-1 HRP Tracer

MP800320T 0.2 mL Ask for price

Anti-Human MCP-3 HRP Tracer

MP800333T 0.2 mL Ask for price

Anti-Human IL-8 Biotin Tracer

MP800120B 0.1 mL Ask for price

IAA tracer (alkaline phospahatase conjugated)

AS09-517 1000 assays
EUR 208

ABA tracer (alkaline phospahatase conjugated)

AS10-726 1000 assays
EUR 230

Anti-Human IL-15 Tracer -Biotin

MP150150T 0.1 mL Ask for price

Anti-Human IL-16 Biotin Tracer

MP160160B 0.1 mL Ask for price

Anti-Human IL-18 Tracer -Biotin

MP180180T 0.1 mL Ask for price

Human GM-CSF HRP Tracer Antibody

MP620120T 0.2 mL Ask for price

Human CRP HRP (poly) Tracer Antibody

MP730730T 0.2 mL Ask for price

Anti-Human MCP-1 Biotin Tracer

MP800320B 0.1 mg Ask for price

Anti-Human MCP-3 Biotin Tracer

MP800333B 0.1 mg Ask for price

Anti-Human TNF Alpha Biotin Tracer

MP500500B 0.5 mg Ask for price

Anti-Human Serum Amyloid HRP Tracer

MP600200T 0.2 mL Ask for price

Human GM-CSF Biotin Tracer Antibody

MP620120B 0.1 mg Ask for price

Human Growth Hormone HRP Tracer Antibody

MP100222T 0.2 mL Ask for price

Anti-Human Serum Amyloid Biotin Tracer

MP600200B 0.1 mL Ask for price

NIR-FLIVO 690 Tracer In vivo Assay

MBS258410-20Tests 20Tests
EUR 535

NIR-FLIVO 690 Tracer In vivo Assay

MBS258410-5x20Tests 5x20Tests
EUR 2460

NIR-FLIVO 747 Tracer In vivo Assay

MBS258412-20Tests 20Tests
EUR 535

NIR-FLIVO 747 Tracer In vivo Assay

MBS258412-5x20Tests 5x20Tests
EUR 2460

Human Growth Hormone Biotin Tracer Antibody

MP100222B 0.1 mg Ask for price

Human Carcinoembryonic Antigen (CEA) HRP Tracer

MP720720T 0.2 mL Ask for price

NIR-FLIVO® 690 Tracer In vivo Assay

9112 20 Tests
EUR 438

NIR-FLIVO® 747 Tracer In vivo Assay

9114 20 Tests
EUR 438

Cis-zeatin tracer (alkaline phospahatase conjugated)

AS16-4092 1000 assays
EUR 230

Trans-zeatin tracer (alkaline phospahatase conjugated)

AS16-4090 1000 assays
EUR 230

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric

CBA-135 96 assays
EUR 596

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric

CBA-135-5 5 x 96 assays
EUR 2592

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric

CBA-140 96 assays
EUR 624

CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric

CBA-140-5 5 x 96 assays
EUR 2700

Anti-Human Prostate Specific Antigen HRP Tracer

MP100444T 0.4 mL Ask for price

Anti-Human Prostate Specific Antigen Biotin Tracer

MP100444B 0.1 mg Ask for price

CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size

CBA-135-T 24 assays
EUR 518.4
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

N6-isopentenyladenosine tracer (alkaline phospahatase conjugated)

AS17-4132 1000 assays
EUR 208

HRP conjugated mAb anti-Human TNF-alpha (Tracer)

MBS592166-02mL 0.2mL
EUR 580

HRP conjugated mAb anti-Human TNF-alpha (Tracer)

MBS592166-5x02mL 5x0.2mL
EUR 2355

Anti-Human Beta Amyloid Peptide 42- BIOTIN TRACER

NS22020B 0.1 mL Ask for price

CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size

CBA-140-T 24 assays
EUR 547.2
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis.

Anti-Human CA 19-9 Tumor Marker - HRP Tracer

MP19920T 200 µL Ask for price

154 patients from Pedi CART19, ELIANA, ENSIGN, and 16CT022 received tisagenlecleucel and 41 patients from the 13BT022 trial received the humanised CD19-directed CAR, huCART19. We categorised patients into two strata on the basis of CNS status at relapse or within the 12 months preceding CAR T-cell infusion-either CNS-positive or CNS-negative disease. Patients with CNS-positive disease were further divided on the basis of morphological bone marrow involvement-either combined bone marrow and CNS involvement, or isolated CNS involvement.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

Role of Nampt overexpression in a rat model of Hashimoto's thyroiditis and its mechanism of action.

Role of Nampt overexpression in a rat model of Hashimoto’s thyroiditis and its mechanism of action.Role of Nampt overexpression in a rat model of Hashimoto’s thyroiditis and its mechanism of action.

The current examine was designed to analyze the function of nicotinamide phosphoribosyltransferase (Nampt) overexpression in a rat mannequin of Hashimoto’s thyroiditis (HT) and its mechanism of motion. A rat mannequin